SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently trending as investors debate the impact of the company's recent earnings report, which showed significant revenue misses alongside continued heavy cash burn. While bears are pointing to these financials as evidence of a failed business model, the community is largely focused on the company's long-term infrastructure roadmap, including upcoming satellite launches and government contracts, with many supporters viewing the post-earnings dip as a buying opportunity.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is seeing heightened trading volume as the community debates whether the asset is initiating a structural breakout fueled by industrial demand, particularly from the AI and chip manufacturing sectors. While some traders are focused on potential short squeezes and aggressive price targets, others are closely monitoring supply chain constraints and the metal's role as a hedge against inflationary pressures.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a massive, polarizing bid to acquire eBay and a proposed authorization to increase shares to 2.5 billion, sparking intense debate over whether this represents a strategic pivot or predatory dilution. The community remains deeply divided, with bulls pointing to the company's significant cash reserves as potential fuel for a transformation, while bears and skeptics express frustration over the company's historical performance and the recent volatility surrounding social media speculation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as retail investors and community members speculate on the potential for its Associative Processing Unit (APU) technology to serve as a breakthrough for edge AI and defense applications. Discussions are heavily polarized, pitting optimistic bulls who point to potential military contracts and high-growth sectors against vocal skeptics who cite management credibility concerns, historical share dilution, and ongoing short-seller skepticism.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark Inc. is currently trending as investors weigh its aggressive pivot into high-performance computing and AI infrastructure against concerns over executive compensation and the lack of a concrete hyperscaler deal. The community is actively debating the company's valuation and the potential for a short squeeze, fueled by volatility in Bitcoin and broader speculation regarding energy-linked assets.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as investors react to strong Q1 results, characterized by a massive revenue jump and a fortified balance sheet that effectively addresses short-seller concerns regarding liquidity. The community is actively discussing its strategic pivot from a research-focused entity to a commercial photonics and hardware provider, with significant debate over its long-term viability versus current valuation.

"What's Updog?" is a Community Led token.

UpDog

UpDog is gaining community momentum as a long-standing Solana-based memecoin, fueled by organic growth and its inclusion on the Jupiter strict list. The community is actively discussing the coin's resilience over its two-year history and focusing on whale accumulation patterns as they aim for increased market visibility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh strong quarterly earnings against margin concerns and broader sector-wide selling. The community remains deeply divided, with many retail investors viewing the pullback as a heavily manipulated buying opportunity while others express frustration over the stock's persistent disconnect from its fundamental growth metrics.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is facing intense volatility as investors weigh a significant earnings miss against raised full-year guidance and long-term growth optimism. The community remains deeply divided, with bulls pointing to the company's expansion into peptide and weight-loss markets as a major catalyst, while bears express skepticism over margins and the sustainability of recent stock performance.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is currently at the center of investor discussion following the release of positive interim Phase 1 data for its ABCL635 candidate, which has triggered a mix of retail excitement and high volatility as market participants debate the company's valuation versus its long-term clinical potential. While the community remains divided between long-term proponents highlighting a robust cash position and upcoming Phase 2 readouts, and skeptics focusing on the stock's recent price stagnation, trading volume has spiked as market participants monitor institutional positioning and potential short-squeeze dynamics ahead of future clinical milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635...

<ul class="summary-bullets"><li>ABCL635 is being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes.</li><li>ABCL is pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines.</li><li>According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’</li></ul>Shares of AbCellera Biologics Inc. (ABCL) continued their strong upward momentum on Friday, as investors gear up for the company’s first-quarter 2026 earnings report and a key clinical catalyst scheduled for Monday.ABCL shares closed up 9% on Friday and edged up 4% after hours. Overall, the stock clocked 18% gains this week, clocking its best week since the last week of February. &nbsp;<h2 class="st-heading-2">Upcoming Catalysts</h2>On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635 being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes — an area with significant unmet medical need and an estimated multi-billion-dollar U.S. market opportunity.AbCellera spent years building an antibody discovery engine and generating revenue primarily through partnerships. It is now deliberately pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines. ABCL635 is the first real test of that shift.The positive sentiment was further reinforced this week by a regulatory filing showing that Baker Bros. Advisors, one of biotech’s most respected institutional investors, has increased its stake in AbCellera to 10.8% of outstanding shares.Wall Street, on average, now expects the firm to report first-quarter revenue of $5.84 million, above the $4.24 million reported in the corresponding quarter of 2025, in addition to a loss per share of $0.19.<h2 class="st-heading-2">Analyst Takeaways</h2>Earlier this week, Cantor Fitzgerald initiated coverage of AbCellera with an ‘Overweight’ rating and $7 price target. According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $9.14, representing a potential upside of about 74% from the last close.<h2 class="st-heading-2">How Did ABCL Retail Traders React?</h2>On Stocktwits, retail sentiment around ABCL stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that the biggest question running up to Monday is how strong the data will be.<stembedurl>https://www.stocktwits.com/StockMacroView/message/652806266</stembedurl>Another user voiced optimism for the catalysts driving the stock higher.<stembedurl>https://www.stocktwits.com/Stocktradesmoon/message/652742650</stembedurl><a href="https://stocktwits.com/symbol/ABCL">ABCL stock</a> has gained 161% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-qure-mrna-soar-on-reports-trump-will-fire-fda-marty-makary/cZX2uTvRegN">REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost 

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.

Equity

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.


Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026 Jefferies Global Healthcare Conference in New York, June 4, 2026 A live audio webcast of each presentation may be accessed through a...

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up   - What's Next?

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Here's Why...

AbCellera Biologics (ABCL) to Release Earnings on Monday

AbCellera Biologics (NASDAQ:ABCL) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a h...

AbCellera Biologics (NASDAQ:ABCL) Shares Down 7.6% - Time to Sell?

AbCellera Biologics (NASDAQ:ABCL) Shares Down 7.6% - Here's Why...

AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes

AbCellera Biologics (NASDAQ:ABCL) is shifting from a partnership-driven discovery business toward advancing its own internally developed clinical pipeline, Chief Financial Officer Andrew Booth said...

$ABCL Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.14 up 6.67% YoY
• Reported revenue of $8.31M up 96.34% YoY

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.14 up 6.67% YoY
• Reported revenue of $8.31M up 96.34% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Technology

Energy

Healthcare

Financials

Stocktwits Polls

Investors are hyper-focused on the clean Phase 1 clinical data for ABCL635 and the anticipation for Q3 Phase 2 efficacy readouts.

The stock is experiencing significant volatility as traders debate 'sell the news' dynamics versus long-term fundamental potential.

ABCL
AbCellera Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest ABCL News

ABCLAbCellera Biologics Inc